Deutsche Märkte geschlossen

Trinity Biotech plc (TRIB)

NasdaqGS - NasdaqGS Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
1,83000,0000 (0,00%)
Börsenschluss: 04:00PM EDT

Trinity Biotech plc

IDA Business Park
Bray A98 H5C8
Ireland
353 1 276 9800
https://www.trinitybiotech.com

Sektor(en)Healthcare
BrancheDiagnostics & Research
Vollzeitmitarbeiter

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Mr. John GillardPresident, CEO, Company Secretary & Director863kN/A1981
Mr. Ronan O'CaoimhFounder & Director340kN/A1956
Dr. James Walsh Ph.D.Executive Director of Business Development & Executive Director20kN/A1958
Mr. Des FitzgeraldInterim Chief Financial OfficerN/AN/AN/A
Mr. Simon DunneChief Accounting OfficerN/AN/A1974
Dr. Gary Keating Ph.D.Chief Technology OfficerN/AN/A1973
Ms. Eibhlin KellyChief Information OfficerN/AN/A1984
Mr. Colm MolloyGroup Director of Human Resources & CultureN/AN/A1971
Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Trinity Biotech plc acquires, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. The company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.

Corporate Governance

Trinity Biotech plcs ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.